Yin et al.
1
1
4. Kiibanov AL, Huang L. Long-Circulating Liposomes:
improved the anti-tumor efficacy and animal survival
rate.
Development and Perspectives. J Liposome Res. 1992;2(3):321–
3
4.
COS may be a promising polymer to stabilize liposomes
with an advantages of enhanced cellular uptake, cost-effec-
tive and possibly good biocompatibility. This study also
highlighted the importance of intracellular ‘detachment’ of
polymer from liposomes through the cleavage of the disulfide
bond in cytoplasmic drug delivery. Taken together, the reduc-
tion (GSH)-sensitive Chol-SS-COS liposomes may be excel-
lent platform for cytoplasmic drug delivery to tumor such as
osteosarcomas.
5. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S,
et al. A pH-sensitive fusogenic peptide facilitates endosomal escape
and greatly enhances the gene silencing of siRNA-containing nano-
particles in vitro and in vivo. J Control Release. 2009;139(2):127–
3
2.
1
6. Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC.
Pegylation of liposomes favours the endosomal degradation of the
delivered phosphodiester oligonucleotides. J Control Release.
2
007;117(2):256–66.
1
1
7. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenom-
enon upon repeated injection of PEGylated liposomes. Int J Pharm.
2
008;354(1-2):56–62.
8. Kierstead PH, Okochi H, Venditto VJ, Chuong TC, Kivimae S,
Frechet JM, et al. The effect of polymer backbone chemistry on the
induction of the accelerated blood clearance in polymer modified
liposomes. J Control Release. 2015;213:1–9.
ACKNOWLEDGMENTS AND DISCLOSURES. This study was
financially supported by Taishan Scholar Project carried out
at School of Pharmacy, Yantai University, funded by
Shandong Province, China. The authors declare that they
have no conflicts of interest to disclose.
19. Qu G, Wu X, Yin L, Zhang C. N-octyl-O-sulfate chitosan-
modified liposomes for delivery of docetaxel: preparation, charac-
terization, and pharmacokinetics. Biomed Pharmacother.
2
012;66(1):46–51.
2
0. Liang G, Jia-Bi Z, Fei X, Bin N. Preparation, characterization and
pharmacokinetics of N-palmitoyl chitosan anchored docetaxel lipo-
somes. J Pharm Pharmacol. 2007;59(5):661–7.
REFERENCES
2
1. Lee SJ, Min HS, Ku SH, Son S, Kwon IC, Kim SH, et al. Tumor-
targeting glycol chitosan nanoparticles as a platform delivery carrier
in cancer diagnosis and therapy. Nanomedicine. 2014;9(11):1697–
1
2
.
.
Jain A, Jain SK. Stimuli-responsive smart liposomes in cancer
targeting. Curr Drug Targets. 2016.
Jhaveri A, Deshpande P, Torchilin V. Stimuli-sensitive
nanopreparations for combination cancer therapy. J Control
Release. 2014;190:352–70.
7
13.
22. Yang Y, Yuan SX, Zhao LH, Wang C, Ni JS, Wang ZG, et al.
Ligand-directed stearic acid grafted chitosan micelles to increase
therapeutic efficacy in hepatic cancer. Mol Pharm. 2015;12(2):
644–52.
23. Huo M, Zhang Y, Zhou J, Zou A, Yu D, Wu Y, et al. Synthesis and
characterization of low-toxic amphiphilic chitosan derivatives and
their application as micelle carrier for antitumor drug. Int J Pharm.
2010;394(1-2):162–73.
3.
4.
5.
Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate
systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):
8
13–27.
Maeda H. The enhanced permeability and retention (EPR) effect
in tumor vasculature: the key role of tumor-selective macromolec-
ular drug targeting. Adv Enzym Regul. 2001;41:189–207.
Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL,
Yamada K, et al. Noninvasive imaging of tumor redox status and
its modification by tissue glutathione levels. Cancer Res.
24. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based
nanoparticles as drug delivery systems. Adv Drug Deliv Rev.
2
008;60(15):1650–62.
2
5. Yan L, Crayton SH, Thawani JP, Amirshaghaghi A, Tsourkas A,
Cheng Z. A pH-responsive drug-delivery platform based on glycol
chitosan-coated liposomes. Small. 2015;11(37):4870–4.
2
002;62(1):307–12.
6
.
Zhou G, Li L, Xing J, Jalde S, Li Y, Cai J, et al. Redox responsive
liposomal nanohybrid cerasomes for intracellular drug delivery.
Colloids Surf B Biointerfaces. 2016;148:518–25.
2
2
6. Lodhi G, Kim YS. Chitooligosaccharide and its derivatives: prep-
aration and biological applications. 2014. ID: 654913.
7. Muanprasat C, Chatsudthipong V. Chitosan oligosaccharide:
Biological activities and potential therapeutic applications.
Pharmacol Ther. 2016;170:80–97.
7
.
.
Latorre A, Somoza A. Glutathione-triggered drug release from
nanostructures. Curr Top Med Chem. 2014;14(23):2662–71.
Felber AE, Dufresne MH, Leroux JC. pH-sensitive vesicles, poly-
meric micelles, and nanospheres prepared with polycarboxylates.
Adv Drug Deliv Rev. 2012;64(11):979–92.
8
2
2
3
8. Zou P, Yang X, Wang J, Li Y, Yu H, Zhang Y, et al. Advances in
characterisation and biological activities of chitosan and chitosan
oligosaccharides. Food Chem. 2016;190:1174–81.
9. Mendis E, Kim MM, Rajapakse N, Kim SK. An in vitro cellular
analysis of the radical scavenging efficacy of chitooligosaccharides.
Life Sci. 2007;80(23):2118–27.
0. Yu J-M, Li Y-J, Qiu L-Y, Jin Y. Self-aggregated nanoparticles of
cholesterol-modified glycol chitosan conjugate: Preparation, char-
acterization, and preliminary assessment as a new drug delivery
carrier. Eur Polym J. 2008;44(3):555–65.
9
.
Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z.
Mechanisms and biomaterials in pH-responsive tumour targeted
drug delivery: A review. Biomaterials. 2016;85:152–67.
1
1
0. Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive
multifunctional liposomal nanocarrier for enhanced tumor
targeting. ACS Nano. 2012;6(4):3491–8.
1. Maruyama K. Intracellular targeting delivery of liposomal drugs to
solid tumors based on EPR effects. Adv Drug Deliv Rev.
3
1. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using
cationic liposomes. Int J Pharm. 2007;337(1-2):329–35.
2
011;63(3):161–9.
1
1
2. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical
nanocarriers. Eur J Pharm Biopharm. 2009;71(3):431–44.
3. Moghimi SM, Hunter AC, Murray JC. Long-circulating and
target-specific nanoparticles: theory to practice. Pharmacol Rev.
32. Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to
tumor vasculature using cationic liposomes. Pharm Res.
2010;27(7):1171–83.
33. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien
DF. Liposome-cell interactions in vitro: effect of liposome surface
2
001;53(2):283–318.